Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Red Hot Deal For Red Heart Pill - Dr. Reddy's In Talks With GSK For Combination Heart Drug

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's Dr. Reddy's Laboratories and pharmaceutical major GlaxoSmithKline are in active discussions to partner on marketing a uniquely designed combination drug that can combat cardiovascular and cerebrovascular diseases and will be priced "very economically.

You may also be interested in...



GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)

GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.

GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)

GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.

GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)

GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel